| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 78,50 | 78,90 | 19:56 | |
| 78,45 | 78,65 | 19:53 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 82,50 | 160 | |||
| 82,40 | 200 | |||
| 82,00 | 32 | |||
| 81,00 | 52 | |||
| 80,85 | 111 | |||
| 80,55 | 1.000 | |||
| 80,40 | 130 | |||
| 80,00 | 86 | |||
| 79,50 | 77 | |||
| 78,80 | 1.160 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/22ua.htm [/URL] | ||||
| 1.056 | 78,60 | |||
| 215 | 78,40 | |||
| 100 | 76,50 | |||
| 100 | 76,00 | |||
| 3 | 75,70 | |||
| 20 | 75,20 | |||
| 20 | 75,05 | |||
| 1 | 75,00 | |||
| 26 | 74,10 | |||
| 50 | 74,00 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 1.591 | 1,891 | 3.008 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 17:35:52 | 77,65 | 873 |
| 17:30:01 | 77,60 | 3 |
| 17:25:35 | 77,50 | 25 |
| 17:25:35 | 77,45 | 162 |
| 17:25:35 | 77,45 | 62 |
| 17:25:35 | 77,45 | 36 |
| 17:23:07 | 77,35 | 40 |
| 17:23:07 | 77,35 | 50 |
| 17:22:50 | 77,40 | 32 |
| 17:20:01 | 77,40 | 87 |
| 17:18:21 | 77,35 | 46 |
| 17:18:06 | 77,35 | 4 |
| 17:16:06 | 77,40 | 25 |
| 17:11:02 | 77,50 | 124 |
| 17:09:38 | 77,40 | 393 |
| 17:09:38 | 77,40 | 10 |
| 17:07:06 | 77,55 | 857 |
| 16:52:20 | 77,70 | 12 |
| 16:49:02 | 77,65 | 487 |
| 16:49:02 | 77,60 | 200 |
| Tagesumsatz Xetra | -0,40 -0,51 % | 28.501 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BIONTECH Aktie jetzt für 0€ handeln | |||||
| 17:30 | EXKLUSIV zu Curevac: Was Insider heute bereits wissen - Was das für Ihr Depot bedeutet | Hebelschein-Spekulant | |||
| Di | Top-Investoren umwerben neues Projekt von Biontech-Gründern - ohne es zu kennen | 74 | FOCUS | ||
| Di | Bill Gates offenbar an neuem Projekt der Biontech-Gründer interessiert | 90 | manager-magazin.de | ||
| Di | Leerink senkt Kursziel für BioNTech wegen Bedenken bei Medikamentenstudie | 205 | Investing.com Deutsch | ||
| Di | Leerink cuts BioNTech stock price target on drug trial concerns | 52 | Investing.com |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 14:33 | EQS-Adhoc: Heidelberg Pharma AG: Heidelberg Pharma legt Dosis für Phase II-Studie (RP2D) mit dem ADC-Kandidaten HDP-101 fest | EQS Group (DE) | EQS-Ad-hoc: Heidelberg Pharma AG / Schlagwort(e): Sonstiges
Heidelberg Pharma AG: Heidelberg Pharma legt Dosis für Phase II-Studie (RP2D) mit dem ADC-Kandidaten HDP-101 fest
09.04.2026... ► Artikel lesen | |
| 17:50 | Strategische Weichenstellung im Exosomenmarkt | Small- & Micro Cap Investment | ||
| 13:02 | Zeo ScientifiX, Inc.: Regen Therapy Partners with Stealth Health to Bring Specialized Telemedicine Services and Longevity Programs to 3,000 Clinics - Powered by an Exclusive Scientific and Biologics Strategic Collaboration with ZEO ScientifiX | ACCESS Newswire | Regen Therapy's 24,000-practitioner network will unlock a fully integrated care ecosystem - featuring Stealth Health's licensed prescriber team and specialized therapies, Metabolic Code-driven longevity... ► Artikel lesen | |
| 15:36 | Tempus AI Expands Collaboration With Gilead Sciences To Maximize Insights In Oncology Pipeline | AFX News | FOSTER CITY (dpa-AFX) - Healthcare technology company Tempus AI, Inc. (TEM) Thursday announced an expanded, multi-year collaboration with Gilead Sciences, Inc. (GILD) to build and advance its... ► Artikel lesen | |
| 14:12 | C4 Therapeutics Enters Collaboration Agreement With Roche | AFX News | SOUTH SAN FRANCISCO (dpa-AFX) - C4 Therapeutics (CCCC) has entered into a new collaboration agreement with Roche (RHHBY, RO.SW, ROG.SW) to advance research in the degrader-antibody conjugate... ► Artikel lesen |